AzTrials
AzTrials

HemorrhoidsPhase 2/3NCT04675177

Polidocanol Foam VS Artery Ligation in Hemorrhoidal Disease

A Phase 2/3 study testing Polidocanol foam sclerotherapy and Doppler-guided hemorrhoidal artery ligation in people with Hemorrhoids, run by Universidade do Porto at 1 site in Portugal.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: Hemorrhoidal disease is extremely frequent in the adult population and, as a benign pathology, the treatment should be guided by the patient's symptoms. Treatment of hemorrhoidal disease includes a conservative approach, office-based treatments and surgery. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Hemorrhoids
What is being tested?
Polidocanol foam sclerotherapy and Doppler-guided hemorrhoidal artery ligation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
45 participants
Where
1 sitePortugal
Study dates
1 Sep 2019to 25 Mar 2020
Phase
Phase 2/3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients older than 18 years with symptomatic hemorrhoidal disease grade II and III (Goligher's classification)
  • Refractory to conservative therapy (dietary modification, intestinal transit modifiers, topical and phlebotonic medications) for a period of not less than 4 weeks

Who cannot join

  • Cirrhosis
  • Pregnant or breast-feeding women
  • Known allergy to polidocanol
  • Another perianal disease that can cause symptoms similar to hemorrhoidal disease
  • Colorectal malignancy
  • Concomitant presence of external hemorrhoidal disease and/or hemorrhoidal thrombosis - - Office or surgical treatment for hemorrhoids within 6 months prior to inclusion
Show all 11Show fewer
  • Antiplatelet or hypocoagulant medication
  • Hematological disorders
  • Immunosuppressive states
  • Inflammatory bowel disease
  • Patients unable to have general or spinal anesthetic

Trial locations and contacts

1 site in 1 country.

Portugal1 site
  • Centro Hospitalar Universitário do Porto

    Porto, 4050-000

Other trials in Portugal

About this study

Official title: Sclerotherapy With Polidocanol Foam Versus Hemorrhoidal Artery Ligation With Recto Anal Repair in the Treatment of Second and Third-grade Hemorrhoidal Disease: a Prospective Study

Background: Hemorrhoidal disease is extremely frequent in the adult population and, as a benign pathology, the treatment should be guided by the patient's symptoms. Treatment of hemorrhoidal disease includes a conservative approach, office-based treatments and surgery.

This study is aimed to evaluate and compare the efficacy and safety of the treatment of hemorrhoidal disease with non-surgical office-based method polidocanol foam sclerotherapy (SP) and the surgical technique doppler-guided hemorrhoidal artery ligation with recto-anal repair.

Read more

Methods: Prospective, unicentric study including patients with symptomatic hemorrhoidal disease grade II and III refractory to conservative therapy, submitted either to SP (n=24) or to HAL-RAR procedure (n=21), during a recruitment period of 6 months.

Patients were evaluated for efficacy (Sodergren's scale of symptoms and severity of bleeding) and safety (complications and implication in personal and professional life), up to one month after treatment. In follow-up period (6 months) participants were evaluated for hemorrhoidal disease recurrence.

Read the detailed description

INTRODUCTION:

Instrumental office-based procedures are usually indicated for internal hemorrhoidal disease grade I and II which are refractory to conservative medical treatments and in selected cases of grade III hemorrhoidal disease. Despite being invasive, these techniques are more conservative than surgical treatments and are also effective. The primary goals are to decrease the amount of redundant tissue, reduce vascularity, and affix the hemorrhoidal cushions to minimize prolapse. Office-based procedures include rubber band ligation (RBL), sclerotherapy (liquid and foam agents), infrared photocoagulation, cryotherapy, radiofrequency ablation among others.

Hemorrhoidal sclerosis is a procedure indicated to treat grade I and II hemorrhoidal disease. It has also been used in the treatment of internal grade III hemorrhoidal disease, but there are limited data on its efficacy. Performed through an anoscope and according to Blanchard technique, internal hemorrhoids are located and injected with a sclerosant material into the submucosa at the base of the hemorrhoid, above the anterolateral line. The sclerosant subsequently causes an inflammatory response and fibrosis that interrupts the vascular blood supply. A variety of sclerosants have been used including ethanolamine, quinine, hypertonic saline, aluminum potassium sulfate and tannic acid (ALTA), and 5% phenol in oil. Recently, a new sclerosing agent, polidocanol, started to be employed in the treatment of hemorrhoidal disease. It is a nonionic detergent and consists of a hydrophilic polyethylene oxide chain combined with hydrophobic aliphatic dodecyl alcohol. When injected into varicose veins, polidocanol damages the endothelium of blood vessels, allowing platelets to aggregate. Eventually, a dense network of platelets, cellular debris, and fibrin occludes the vessel, which is subsequently replaced with connective fibrous tissue. In addition to the treatment of hemorrhoidal disease, polidocanol is used for sclerotherapy of varicose veins of the lower extremities and for the treatment of esophageal varices. The advantages of this sclerosing agent include a highly satisfactory efficiency, a low necrotic potential, and a good general tolerance. At the same time, it has a local anesthetic effect which permits almost painless sclerotherapy. Nevertheless, its use is contraindicated in patients with acute thromboembolic diseases and in those with allergy to the drug. Polidocanol can be used in its liquid or foam form. It has been proved the foam formulation allows for greater efficacy, since it requires lower doses of sclerosant agent. This is because the sclerotic effect is maximized by increasing the contact surface area with varices walls. This foam is previously prepared according to the Tessari's method, in which two 10 mL syringes are connected by a 3-way stopcock. The syringes contain air and a sclerosing agent (3% polydocanol), with a ratio of 4:1, respectively, and twenty passages from one syringe to the other are made in order to obtain a sclerosing foam. Several studies reported the efficacy of the use of sclerotherapy with liquid polidocanol in hemorrhoidal disease. Specifically for the treatment of grade I hemorrhoids, there is one study showing the superiority of polidocanol foam compared to its liquid formulation. However, there's a lack of research about its use in hemorrhoidal disease other than grade I. The most common complications of sclerotherapy include minor discomfort or bleeding. Although it is a very safe treatment option, some serious side effects, including erectile dysfunction and urinary retention, have been reported. The proper injection technique of sclerosant is essential to avoid complications such as mucosal ulceration or necrosis, prostatic abscess and retroperitoneal sepsis. Sclerotherapy is a valid alternative when conservative therapy has failed. Moreover, this procedure can also be used for the treatment of patients whose hemorrhage is the main symptom, for patients on antithrombotic medication, as well as cirrhotic and immunocompromised patients.

Surgical treatment is reserved for refractory cases to nonsurgical approaches, grade IV or mixed hemorrhoidal disease (internal and external components), symptomatic hemorrhoidal disease with concomitant anorectal pathology and lastly if it's the patient's choice. Although surgical approach is apparently more effective than instrumental treatment, it is also associated with substantial postsurgical morbidity, particularly postoperative pain and limitation in day-life activities. Several surgical methods have been described including open and closed hemorrhoidectomy, doppler guided hemorrhoidal artery ligation (HAL) and hemorrhoidectomy stapler. The choice of each method should consider the grade of hemorrhoidal disease and the predominant symptoms of the patient, together with the experience of the center.

HAL technique involves the use of Doppler ultrasound and a specialized anoscope. The principles include the use of a Doppler probe to identify the six main feeding arteries within the anal canal and their ligation with absorbable suture above the dentate line, therefore associated with less pain. Finally, plication of redundant hemorrhoidal mucosa is performed (if there is hemorrhoidal or muco-hemorrhoidal prolapse), known as recto-anal-repair (RAR), mucopexy or hemorrhoidopexy. The aim of this recent surgical procedure is to treat patients' symptoms without tissue destruction. Early results of HAL were promising, with lower pain scores than hemorrhoidectomy, and relief of bleeding and tissue prolapse in over 90% of patients. Since then, several randomized clinical trials have been performed with mixed results. Currently, HAL remains a viable approach to multicolumn internal hemorrhoids. However, the short-term benefits regarding postoperative pain have recently not been as remarkable as in the earlier studies. Also, there has been a progressive increase in long term recurrence rates, especially for grade III and IV hemorrhoids.

Some studies have been conducted with the purpose of comparing the efficacy of nonsurgical office-based treatments with surgical ones.

A multicentric, open-label, randomized controlled trial, compared RBL and HAL, revealing higher efficacy of the surgical procedure. If, however, RBL is considered a course of treatment involving repeat banding, the procedures are equally effective. Besides, HAL was proved to be more painful than RBL. Another study comparing infrared photocoagulation with HAL showed that both procedures are minimally invasive and associated with minimal discomfort, but HAL is more effective than infrared photocoagulation in controlling symptoms of hemorrhoids. There has been no comparative studies between polidocanol foam sclerotherapy and hemorrhoidal artery ligation, to date.

Therefore, the purpose of the present study is to evaluate and compare the safety and efficacy of the treatment of hemorrhoidal disease with polidocanol foam sclerotherapy and HAL-RAR.

METHODS:

Prospective, unicentric study (Centro Hospitalar Universitário do Porto) which is aimed to compare the efficacy and safety of the treatment techniques in patients with hemorrhoidal disease grade II and III.

Patients referred were randomly allocated to one of the two treatments considered in this study (SP and HAL-RAR).

All participants should have had prior endoscopic study, at least sigmoidoscopy, or total colonoscopy if they were older than 50 years or younger, with a family history of colorectal cancer, colon adenomas, or suspected inflammatory bowel disease.

Only patients who agreed to informed consent were included, after a clear explanation of the type of study and the intervention that was going to be made.

In screening visits, demographic and anthropometric data (such as age, sex, weight and height, education and employment status) were collected, as well as grade of hemorrhoidal disease. Baseline questionnaires were used to assess Sodergren's scale of symptoms and the severity of bleeding.

Informed consent and an information brochure, explaining the study and adequate dietary and behavioral care, were provided. Additionally, all participants were given a direct contact for any doubts and notification of complications, in which case additional observation should be made.

When office-based treatment was performed, an intervention period was considered, in which patients were observed at 3-week intervals (the required number of sessions, maximum of 3, depended on the clinical response - if 3 weeks after the previous treatment, the participant scored zero points in the Sodergren scale and had a hemorrhage grade ≤1, he was not a candidate for additional instrumental therapy.).

Surgical treatment was performed only once. One month after this intervention period, Sodergren's scale of symptoms and severity of bleeding were reevaluated. In addition, complications registry, and implication in personal and professional life, measured in number of work-loss days, if applied, were also assessed. Patients was followed-up every 3 months for total of 6 months for evaluation of hemorrhoidal disease symptoms recurrence.

Conditions
Hemorrhoids
Being tested
Polidocanol foam sclerotherapy, Doppler-guided hemorrhoidal artery ligation
Keywords
Hemorrhoids, Sclerotherapy, polidocanol foam, Doppler-guided hemorrhoidal artery ligation
Medical subject headings
Hemorrhoids

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Polidocanol foam sclerotherapyDrug

    Also called Aethoxysklerol 3%)

    1. Patients underwent preparation, two hours before the intervention, with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed. ii. Preparation of the polidocanol (Aethoxysklerol 3%) foam according to Tessari technique immediately before application, so that the "microbubbles" of the foam did not disintegrate; iii. The procedure was performed in the medical office. Application according to the Blanchard technique through a disposable transparent anoscope, in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle; iv. Patients were treated in a maximum of 3 sessions, at 3 weeks intervals; v. Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air; i. In each session, the sclerosant was injected in one or more hemorroidary cushion;
  • Doppler-guided hemorrhoidal artery ligationProcedure or surgery

    Also called HAL-RAR

    1. Patients underwent preparation with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed. ii. The procedure was performed in the operating room of an outpatient surgery unit, under regional anestesia. iii. A proctoscope with a Doppler transducer in its tip was introduced inside the anal canal to search for the superior rectal artery. iv. Each branch was ligated with suture above the dentate line. The device was rotated slowly in clockwise direction to locate further arteries at that level.
    2. Rectoanal repair consisted in a continuous running suture was applied longitudinally just over every prolapsed hemorrhoid.
Study groups in NCT04675177
Study groupRoleWhat they receive
Polidocanol foam sclerotherapyActive comparatorPatients submitted to polidocanol foam sclerotherapy
Receives: Drug: Polidocanol foam sclerotherapy
Doppler-guided hemorrhoidal artery ligationActive comparatorPatients submitted to doppler-guided hemorrhoidal artery ligation
Receives: Procedure: Doppler-guided hemorrhoidal artery ligation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Therapeutic success

    Efficacy indicator composed by Sodergren score and bleeding grade:

    • Complete (Sodergren score = 0 and bleeding grade <= 1);
    • Partial (Sodergren score > 0 and bleeding grade > 1 but, at least, one of them with improvement, regarding the initial score, and none of them worse);
    • Therapeutic failure (participants that, one month after the last instrumental treatment or one month after surgery, worsened or maintained the initial Sodergren score and bleeding grade);

    Measured: 3 months

  2. Safety evaluation

    Record of complications resulting from the therapy:

    • Mild (e.g. pain/discomfort, pruritus, bleeding grade 1)
    • Moderate (e.g., external hemorrhoidal thrombosis, bleeding without hemodynamic instability, no blood transfusion, no need for haemostasis or urgent surgery): do not endanger the patient's life or leave long term sequelae;
    • Severe (e.g. sepsis, Fournier's gangrene, perineal abscess, bleeding with hemodynamic instability, transfusional need or urgent surgery, sexual impotence in man): they put the patient's life at risk.

    Measured: 3 Months

Secondary outcomes (4)
  1. Professional life implications

    Implications in professional life were measured in number of work-loss days

    Measured: 3 months

  2. Personal life implications

    Outcome assessed with some simple yes-no questions (eg: personal and family relationships, sexual activity, physical exercise, social and civic activities), and if at least one of them was answered affirmatively, we considered treatment had significant impact in patient's personal life.

    Measured: 3 months

  3. Number of treatment sessions

    Number of instrumental treatment sessions required

    Measured: 3 months

  4. Recurrence

    Evaluation of symptoms recurrence during de follow-up period

    Measured: 6 Months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Dec 2020
  2. Study start1 Sep 2019
  3. Primary completion1 Feb 2020
  4. Study completion25 Mar 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Prospective, unicentric study (Centro Hospitalar Universitário do Porto (CHUP)) which is aimed to compare the efficacy and safety of the treatment techniques in patients with hemorrhoidal disease grade II and III. Patients referred to consultation were randomly allocated to one of the two treatments (polidocanol foam sclerotherapy and hemorrhoid artery ligation +- rectoanal repair).
Masking
None (open label)
Enrolment
45 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04675177
Sponsor's protocol ID
514741899
Status last verified
Feb 2021
First submitted
14 Dec 2020
Last updated
10 Feb 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Study data can shared upon justified request

Publications

  • Sun Z, Migaly J. Review of Hemorrhoid Disease: Presentation and Management. Clin Colon Rectal Surg. 2016 Mar;29(1):22-9. doi: 10.1055/s-0035-1568144.

    PubMed 26929748
  • Sneider EB, Maykel JA. Diagnosis and management of symptomatic hemorrhoids. Surg Clin North Am. 2010 Feb;90(1):17-32, Table of Contents. doi: 10.1016/j.suc.2009.10.005.

    PubMed 20109630
  • Rakinic J, Poola VP. Hemorrhoids and fistulas: new solutions to old problems. Curr Probl Surg. 2014 Mar;51(3):98-137. doi: 10.1067/j.cpsurg.2013.11.002. Epub 2013 Nov 25.

    PubMed 24606821
  • Lohsiriwat V. Hemorrhoids: from basic pathophysiology to clinical management. World J Gastroenterol. 2012 May 7;18(17):2009-17. doi: 10.3748/wjg.v18.i17.2009.

    PubMed 22563187
  • Lohsiriwat V. Approach to hemorrhoids. Curr Gastroenterol Rep. 2013 Jul;15(7):332. doi: 10.1007/s11894-013-0332-6.

    PubMed 23715885
  • Peery AF, Sandler RS, Galanko JA, Bresalier RS, Figueiredo JC, Ahnen DJ, Barry EL, Baron JA. Risk Factors for Hemorrhoids on Screening Colonoscopy. PLoS One. 2015 Sep 25;10(9):e0139100. doi: 10.1371/journal.pone.0139100. eCollection 2015.

    PubMed 26406337
  • Faccini M, Zuccon W, Caputo P, Gavezzoli D, Manelli A, Bonandrini L. [Hemorrhoids: epidemiology and correlation with chronic constipation]. Ann Ital Chir. 2001 May-Jun;72(3):337-9; discussion 340. Italian.

    PubMed 11765352
  • Pigot F, Siproudhis L, Allaert FA. Risk factors associated with hemorrhoidal symptoms in specialized consultation. Gastroenterol Clin Biol. 2005 Dec;29(12):1270-4. doi: 10.1016/s0399-8320(05)82220-1.

    PubMed 16518286
  • Riss S, Weiser FA, Schwameis K, Riss T, Mittlbock M, Steiner G, Stift A. The prevalence of hemorrhoids in adults. Int J Colorectal Dis. 2012 Feb;27(2):215-20. doi: 10.1007/s00384-011-1316-3. Epub 2011 Sep 20.

    PubMed 21932016
  • Johanson JF, Sonnenberg A. The prevalence of hemorrhoids and chronic constipation. An epidemiologic study. Gastroenterology. 1990 Feb;98(2):380-6. doi: 10.1016/0016-5085(90)90828-o.

    PubMed 2295392
  • Lohsiriwat V. Treatment of hemorrhoids: A coloproctologist's view. World J Gastroenterol. 2015 Aug 21;21(31):9245-52. doi: 10.3748/wjg.v21.i31.9245.

    PubMed 26309351
  • Hollingshead JR, Phillips RK. Haemorrhoids: modern diagnosis and treatment. Postgrad Med J. 2016 Jan;92(1083):4-8. doi: 10.1136/postgradmedj-2015-133328. Epub 2015 Nov 11.

    PubMed 26561592
  • Qureshi WA. Office management of hemorrhoids. Am J Gastroenterol. 2018 Jun;113(6):795-798. doi: 10.1038/s41395-018-0020-0. No abstract available.

    PubMed 29487411
  • Pucher PH, Qurashi M, Howell AM, Faiz O, Ziprin P, Darzi A, Sodergren MH. Development and validation of a symptom-based severity score for haemorrhoidal disease: the Sodergren score. Colorectal Dis. 2015 Jul;17(7):612-8. doi: 10.1111/codi.12903.

    PubMed 25603811
  • Rorvik HD, Styr K, Ilum L, McKinstry GL, Dragesund T, Campos AH, Brandstrup B, Olaison G. Hemorrhoidal Disease Symptom Score and Short Health ScaleHD: New Tools to Evaluate Symptoms and Health-Related Quality of Life in Hemorrhoidal Disease. Dis Colon Rectum. 2019 Mar;62(3):333-342. doi: 10.1097/DCR.0000000000001234.

    PubMed 30451751

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Polidocanol foam sclerotherapy and Doppler-guided hemorrhoidal artery ligation in people with Hemorrhoids, run by Universidade do Porto at 1 site in Portugal.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Therapeutic success (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04675177, which also lists 58 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in